Ou Ruwei, Wei Qianqian, Hou Yanbing, Zhang Lingyu, Liu Kuncheng, Lin Junyu, Yang Tianmi, Yang Jing, Jiang Zheng, Song Wei, Cao Bei, Shang Huifang
Department of Neurology, Laboratory of Neurodegenerative Disorders, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, China.
J Clin Med. 2022 Oct 19;11(20):6163. doi: 10.3390/jcm11206163.
Estrogen not only plays a key role in the decreased risk of Parkinson's disease (PD) but also influences its severity. We aimed to explore the effect of the reproductive lifespan on the motor progression of PD female patients in a large prospective cohort study.
A competing risk analysis with a Fine and Gray model on 491 female and 609 male patients with PD was conducted. We regarded the chance of faster motor progression (as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) III increasing by ≥16 points during follow-up) and the chance of death as competing risks. The reproductive lifespan was regarded as the variable of interest, while faster motor progression was set as the primary outcome.
In the multivariable competing risk analysis, the male sex was not significantly associated with faster motor progression (subdistribution hazard ratio (SHR) 0.888, 95% CI 0.652-1.209, = 0.450), while a shorter reproductive lifespan was associated with faster motor progression in women (SHR 0.964, 95% CI 0.936-0.994, = 0.019). Sensitivity analysis indicated that a shorter reproductive lifespan was also significantly associated with faster motor progression in the 48 female patients who reported menopause after the onset of PD (SHR 0.156, 95% CI 0.045-0.542, = 0.003). A linear mixed model also revealed the significant main effects of a short reproductive lifespan on the higher UPDRS III score in PD female patients at the last visit ( = 0.026).
Our study indicates that a short reproductive lifespan contributes to faster motor progression in PD female patients, which has important implications for understanding the role of endogenous estrogen exposure in female PD and is beneficial to select appropriate patients in clinical trials.
雌激素不仅在降低帕金森病(PD)风险中起关键作用,还会影响其严重程度。我们旨在通过一项大型前瞻性队列研究,探讨生殖寿命对PD女性患者运动进展的影响。
对491例女性和609例男性PD患者进行了基于Fine和Gray模型的竞争风险分析。我们将更快运动进展的可能性(通过随访期间统一帕金森病评定量表(UPDRS)III增加≥16分来衡量)和死亡可能性视为竞争风险。生殖寿命被视为感兴趣的变量,而更快运动进展被设定为主要结局。
在多变量竞争风险分析中,男性与更快运动进展无显著关联(亚分布风险比(SHR)0.888,95%置信区间0.652 - 1.209,P = 0.450),而生殖寿命较短与女性更快运动进展相关(SHR 0.964,95%置信区间0.936 - 0.994,P = 0.019)。敏感性分析表明,在48例PD发病后报告绝经的女性患者中,生殖寿命较短也与更快运动进展显著相关(SHR 0.156,95%置信区间0.045 - 0.542,P = 0.003)。线性混合模型还显示,生殖寿命较短对PD女性患者末次就诊时较高的UPDRS III评分有显著的主效应(P = 0.026)。
我们的研究表明,生殖寿命较短会导致PD女性患者运动进展更快,这对于理解内源性雌激素暴露在女性PD中的作用具有重要意义,并且有利于在临床试验中选择合适的患者。